Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise in advanced skin cancer trial

NCT ID NCT04640545

First seen Sep 30, 2025 · Last updated May 25, 2026 · Updated 33 times

Summary

This early-phase study tested a new drug called LBL-007 combined with two other medications (toripalimab and axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety and find the best dose. Researchers also looked at whether tumors shrank. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350000, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410006, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130021, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, 210008, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.